TABLE 1.
Summary of plasma tenofovir, emtricitabine, and rilpivirine pharmacokinetic parameters obtained following drug intake cessationa
| Parameter | Values (90% CI [CV%]) (n = 18) |
||
|---|---|---|---|
| Tenofovir | Emtricitabine | Rilpivirine | |
| AUC0–24 | 2,573 ng · h/ml (2,342–3,208 [40]) | 8,537 ng · h/ml (7,860–11,955 [53]) | 2,116 ng · h/ml (1,929–2,527 [34]) |
| AUC0–last | 4,249 ng · h/ml (3,860–5,325 [41]) | 11,126 ng · h/ml (10,169–15,075 [50]) | 7,271 ng · h/ml (6,635–8,761 [36]) |
| Cmax | 227 ng/ml (208–280 [38]) | 1,260 ng/ml (1,148–1,925 [65]) | 139 ng/ml (128–168 [35]) |
| C24 | 53.3 ng/ml (48.8–71.1 [48]) | 64.7 ng/ml (58.2–97.3 [65]) | 76.3 ng/ml (68.7–94.8 [41]) |
| TE half-life | 30.7 h (27.2–39.7 [48]) | 40.5 h (35.8–53.5 [51]) | 47.2 h (41.3–59.3 [46]) |
a
Data are presented as geometric means (90% CI). AUC0–24, area under the curve over 24 h postdose; AUC0–last, area under the curve to the last measureable concentration within 216 h (0 to 216 for plasma rilpivirine); Cmax, maximum concentration; C24, concentration 24 h postdose; TE half-life, terminal elimination half-life to the last measureable concentration within 216 h (0 to 216 h for plasma rilpivirine).